Piramal Pharma Limited (PPLPHARMA) - Total Liabilities
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has total liabilities worth Rs81.16 Billion INR (≈ $877.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Piramal Pharma Limited (PPLPHARMA) cash conversion ratio to assess how effectively this company generates cash.
Piramal Pharma Limited - Total Liabilities Trend (2021–2025)
This chart illustrates how Piramal Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Check Piramal Pharma Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.
Piramal Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Piramal Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Krungthai Card Public Company Limited
BK:KTC-R
|
Thailand | ฿66.51 Billion |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
USA | $2.04 Billion |
|
Foot Locker Inc
NYSE:FL
|
USA | $3.93 Billion |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
China | CN¥1.74 Billion |
|
Suzhou Gold Mantis Construction Decoration Co Ltd
SHE:002081
|
China | CN¥19.71 Billion |
|
Inv La Constru
SN:ILC
|
Chile | CL$16.08 Trillion |
|
Braze Inc
NASDAQ:BRZE
|
USA | $438.89 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Piramal Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Piramal Pharma Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Piramal Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Piramal Pharma Limited (2021–2025)
The table below shows the annual total liabilities of Piramal Pharma Limited from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs75.52 Billion ≈ $816.73 Million |
+2.05% |
| 2024-03-31 | Rs74.00 Billion ≈ $800.33 Million |
-4.50% |
| 2023-03-31 | Rs77.49 Billion ≈ $838.03 Million |
+27.02% |
| 2022-03-31 | Rs61.00 Billion ≈ $659.74 Million |
+268.37% |
| 2021-03-31 | Rs16.56 Billion ≈ $179.10 Million |
-- |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more